Navigation Links
Stereotaxis Appoints David Burkhardt, M.D. as Chief Medical Officer

Former Electrophysiologist at Cleveland Clinic Brings Extensive Experience in the Use of Interventional Magnetic Navigation Systems in the Treatment

of Cardiovascular Disease

ST. LOUIS, Jan. 17 /PRNewswire-FirstCall/ -- Stereotaxis, Inc. (Nasdaq: STXS) announced today the appointment of J. David Burkhardt, M.D., F.A.C.C., as Chief Medical Officer. Dr. Burkhardt was most recently the Associate Program Director for the Clinical Cardiac Electrophysiology Fellowship training program and he directed the Clinical Electrophysiology curriculum at the Lerner Case Western Reserve School of Medicine at the Cleveland Clinic.

"We are very pleased that David has joined the Stereotaxis executive team," said Bevil J. Hogg, Chief Executive Officer of Stereotaxis. "He is renowned in the field of cardiac electrophysiology and has extensive experience in the use of robotic navigation systems, including the Stereotaxis Niobe System. Through his authorship of numerous peer-reviewed publications and abstracts, as well as speaking engagements at professional conferences worldwide, David has established himself as an expert in his field. He brings a much-valued perspective as a practicing cardiac electrophysiologist to Stereotaxis' mission to provide the safest, most effective standard of care in the treatment of cardiac arrhythmias."

"I am thrilled to be joining Stereotaxis at this very important time, with the FDA approval of the irrigated tip catheter," said Dr. Burkhardt. "While at the Cleveland Clinic, I had the opportunity to evaluate several new technologies, and performed more than 300 cases with the Stereotaxis Niobe System. I believe that Stereotaxis has the ability to revolutionize the way electrophysiology and interventional procedures are performed."

Dr. Burkhardt is board certified in Internal Medicine, Cardiovascular Medicine and Clinical Cardiac Electrophysiology. He received his Bachelor's and Medical degrees from the University of Louisville. Following graduation, Dr. Burkhardt received special training in Internal Medicine and Cardiovascular Medicine. He spent two years in specialized Cardiac Electrophysiology training at the Cleveland Clinic under Dr. Andrea Natale. After completing his training, he accepted a staff position in Cardiovascular Medicine as an Electrophysiologist at the Cleveland Clinic. His specialties include remote navigation, new technology assessment and optimization of Cardiac Resynchronization Therapy. In 2005, he was appointed Associate Program Director at the Cleveland Clinic. He has authored or co-authored over 30 peer-reviewed publications, 10 book chapters, 100 abstracts and he has presented at numerous national and international professional meetings.

About Stereotaxis

Stereotaxis designs, manufactures and markets an advanced cardiology instrument control system for use in a hospital's interventional surgical suite to enhance the treatment of coronary artery disease and arrhythmias. The Stereotaxis System is designed to enable physicians to complete more complex interventional procedures by providing image guided delivery of catheters and guidewires through the blood vessels and chambers of the heart to treatment sites. This is achieved using computer-controlled, externally applied magnetic fields that govern the motion of the working tip of the catheter or guidewire, resulting in improved navigation, shorter procedure time and reduced x-ray exposure. The core components of the Stereotaxis system have received regulatory clearance in the U.S., Europe and Canada.

About Forward Looking Statements

This press release includes statements that may constitute "forward-looking" statements, usually containing the words "believe," "estimate," "project," "expect" or similar expressions. Forward-looking statements inherently involve risks and uncertainties that could cause actual results to differ materially from the forward-looking statements. Factors that would cause or contribute to such differences include, but are not limited to, continued acceptance for the Company's products in the marketplace, competitive factors, changes in government reimbursement procedures, dependence upon third-party vendors, and other risks discussed in the Company's periodic and other filings with the Securities and Exchange Commission. By making these forward-looking statements, the Company undertakes no obligation to update these statements for revisions or changes after the date of this release. There can be no assurance that we will recognize revenue related to our purchase orders and other commitments in any particular period or at all because some of these purchase orders and other commitments are subject to contingencies that are outside of our control. In addition, these orders and commitments may be revised, modified or canceled, either by their express terms, as a result of negotiations, or by project changes or delays.

SOURCE Stereotaxis, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Stereotaxis Niobe System Used to Perform More Than 10,000 Procedures Worldwide
2. Stereotaxis Announces FDA Approval of Its Partnered Magnetic Irrigated Catheter
3. BioVex Appoints Dr. Thaddeus Pullano as VP, Quality Assurance
4. Codexis Appoints Singapore Laboratories Managing Director
5. Emisphere Technologies, Inc. Appoints Paul Lubetkin as Vice President and General Counsel
6. Nektar Therapeutics Appoints Tim Harkness as Chief Financial Officer
7. Anadys Pharmaceuticals Appoints Steve Worland, Ph.D. as President and Chief Executive Officer
8. NanoLogix Inc. Appoints Director of IP and Makes Progress on Rapid Anthrax Detection
9. Emisphere Technologies, Inc. Appoints Michael R. Garone chief financial officer
10. Nektar Therapeutics Appoints Lutz Lingnau as New Board Member
11. NeurogesX Appoints New Director to the Board
Post Your Comments:
(Date:11/30/2015)... Nov. 30, 2015  Northwest Biotherapeutics (NASDAQ: NWBO ... personalized immune therapies for solid tumor cancers, announced today ... independent director, and the Company welcomes Neil Woodford,s ... a recent anonymous internet report on NW Bio.  The ... Linda Powers stated, "We agree with Mr. ...
(Date:11/27/2015)... ... November 27, 2015 , ... Pittcon is pleased to ... presentations offered in symposia, oral sessions, workshops, awards, and posters. The core ... of applications such as, but not limited to, biotechnology, biomedical, drug discovery, environmental, ...
(Date:11/25/2015)... 2015  PharmAthene, Inc. (NYSE MKT: PIP) announced  today ... rights plan (Rights Plan) in an effort to preserve ... under Section 382 of the Internal Revenue Code (Code). ... use of its NOLs could be substantially limited if ... Section 382 of the Code. In general, an ownership ...
(Date:11/25/2015)... QUEBEC CITY , Nov. 25, 2015 /PRNewswire/ ... "Company"), affirms that its business and prospects remain ... , Zoptrex™ (zoptarelin doxorubicin) recently received DSMB ... program to completion following review of the final ... met Phase 2 Primary Endpoint in men with ...
Breaking Biology Technology:
(Date:11/9/2015)... 2015 ... "Global Law Enforcement Biometrics Market 2015-2019" ... ) has announced the addition ... Market 2015-2019" report to their offering. ... ) has announced the addition of ...
(Date:11/2/2015)... , Nov. 2, 2015  SRI International has ... to provide preclinical development services to the National Cancer ... SRI will provide scientific expertise, modern testing and support ... of preclinical pharmacology and toxicology studies to evaluate potential ... --> The PREVENT Cancer Drug Development Program is ...
(Date:10/29/2015)... , Oct. 29, 2015 Daon, a global ... it has released a new version of its ... North America have already installed ... also includes a FIDO UAF certified server component ... preparing to activate FIDO features. These customers include some ...
Breaking Biology News(10 mins):